Department of Radiation Oncology, Stanford University, Stanford, California.
College of Medicine, University of Nebraska, Omaha, Nebraska.
Pract Radiat Oncol. 2021 Mar-Apr;11(2):e134-e138. doi: 10.1016/j.prro.2020.07.006. Epub 2020 Aug 12.
Reproductive toxicity is common after total body irradiation (TBI) and has major quality of life implications for patients. In that context, this is the first report of gonadal-sparing volumetric-modulated arc therapy (VMAT) TBI, successfully delivered in a boy and a girl with aplastic anemia. Both patients' VMAT TBI plans demonstrated improved gonadal sparing versus simulated conventional 2-dimensional (2D) approach (mean testes dose, 0.45 Gy VMAT vs 0.72 Gy 2D; mean ovary dose, 0.64 Gy VMAT vs 1.47 Gy 2D). Planning target volume coverage was also improved for both cases with the VMAT plan versus conventional 2D plan (2 Gy D90% vs 1.9 Gy D90%, respectively). Given these dosimetric advantages, the present study can serve as a proof-of-concept for further prospective studies evaluating this technique for wider applications in populations receiving TBI.
全身照射(TBI)后常发生生殖毒性,对再生障碍性贫血患者的生活质量有重大影响。在此背景下,这是首例成功应用于一男一女患者的性腺保护容积调强弧形治疗(VMAT)TBI 的报告。与模拟常规二维(2D)方法相比,两名患者的 VMAT TBI 计划均显示出更好的性腺保护(睾丸剂量均值,VMAT 为 0.45Gy,2D 为 0.72Gy;卵巢剂量均值,VMAT 为 0.64Gy,2D 为 1.47Gy)。与常规 2D 计划相比,VMAT 计划也改善了两个病例的计划靶区覆盖(2Gy D90%分别为 1.9Gy D90%)。鉴于这些剂量学优势,本研究可作为进一步前瞻性研究的概念验证,以评估该技术在接受 TBI 的人群中的更广泛应用。